Levi & Korsinsky notifies investors that it has commenced an investigation into XBiotech Inc. (NASDAQ: XBIT) concerning potential violations of the federal securities laws.
XBiotech announced on December 23, 2024, that it was pausing a phase 2 rheumatoid arthritis program after the candidate, Natrunix, failed to meet its primary endpoint. Specifically, the Company noted that "substantial irregularities that make unequivocal interpretation of the findings difficult." Following this news, XBiotech's stock price sharply fell during intraday trading on the same day.
If you suffered a loss on your XBiotech Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





